Nimotuzumab: Phase II discontinued

YM discontinued a double-blind, placebo-controlled, international Phase II trial evaluating radiotherapy with and without 200 mg IV nimotuzumab given weekly in 88 patients due to slow enrollment rates. In February, the biotech said it was evaluating whether to discontinue the trial and focus on advanced trials involving partner Daiichi Sankyo, including a planned pivotal trial of nimotuzumab in gastric cancer (see BioCentury, Feb 21). ...